On September 1, 2025 TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the development of novel therapies for cancer and eye diseases, reported that the transaction announced last August 25th has now been completed with €500k in cash received by the Company August 28th (Press release, TME Pharma, SEP 1, 2025, View Source [SID1234655614]). The cash position of TME Pharma is up to €2.35M, showing the good progress of the new cost-efficient organization.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Now that TME Pharma has implemented the lower cost-base model, it will be more able to attract partners for the development of new therapies for cancer and eye diseases. TME Pharma still has high expectations for its NOX-A12 and NOX-E36 programs. TME Pharma will keep informing the markets about the progress it is making.

CEO Van den Ouden will continue to use his experience and expertise to implement the Company’s treasury investment strategy to properly balance risk and return to achieve optimal results for shareholders. TME Pharma is continuing to search for suitable crypto and crypto related candidates for the treasury investment strategy but has no current exposure to crypto.